Jacobs Levy Equity Management, Inc Macrogenics Inc Transaction History

Jacobs Levy Equity Management, Inc

$25.8 Billion
Q4 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 565,904 shares of MGNX stock, worth $1.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

565,904

Previous 566,328 0.07%

Holding current value

$1.18 Million

Previous $1.86 Million 1.29%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$3.18 - $4.46 $1,348 - $1,891	-424 Reduced 0.07%	565,904 $1.84 Million
Q3 2024 Nov 14, 2024	BUY	$3.0 - $5.55 $442,314 - $818,280	147,438 Added 35.2%	566,328 $1.86 Million
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $896,586 - $5.01 Million	270,872 Added 183.0%	418,890 $1.78 Million
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $322,791 - $709,347	33,039 Added 28.73%	148,018 $2.18 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $1.27 Million - $2.88 Million	-284,505 Reduced 71.22%	114,979 $1.11 Million
Q3 2023 Nov 16, 2023	SELL	$4.48 - $6.19 $24,648 - $34,057	-5,502 Reduced 1.36%	399,484 $1.86 Million
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $465,991 - $760,514	100,864 Added 33.17%	404,986 $2.17 Million
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $1.2 Million - $1.8 Million	248,386 Added 445.65%	304,122 $2.18 Million
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $186,158 - $389,037	55,736 New	55,736 $373,000
Q2 2022 Aug 15, 2022	SELL	$2.25 - $9.99 $218,250 - $969,030	-97,000 Reduced 57.66%	71,224 $210,000
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $1.37 Million - $2.84 Million	168,224 New	168,224 $1.48 Million
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $358,774 - $480,584	-18,484 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$24.69 - $31.6 $4.74 Million - $6.07 Million	-192,152 Reduced 91.22%	18,484 $466,000
Q2 2020 Aug 17, 2020	SELL	$5.2 - $29.12 $61,406 - $343,878	-11,809 Reduced 5.31%	210,636 $5.88 Million
Q1 2020 May 15, 2020	BUY	$4.28 - $12.11 $952,064 - $2.69 Million	222,445 New	222,445 $1.3 Million
Q2 2019 Aug 13, 2019	SELL	$14.51 - $19.71 $497,693 - $676,053	-34,300 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$11.11 - $25.6 $1.21 Million - $2.78 Million	-108,566 Reduced 75.99%	34,300 $617,000
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $58,750 - $107,100	5,000 Added 3.63%	142,866 $1.81 Million
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $217,715 - $265,191	-11,304 Reduced 7.58%	137,866 $2.96 Million
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $559,239 - $697,494	28,273 Added 23.39%	149,170 $3.08 Million
Q1 2018 May 15, 2018	SELL	$18.89 - $32.46 $512,655 - $880,931	-27,139 Reduced 18.33%	120,897 $3.04 Million
Q4 2017 Feb 13, 2018	BUY	$16.19 - $20.3 $1.21 Million - $1.51 Million	74,485 Added 101.27%	148,036 $2.81 Million
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $840,578 - $1.03 Million	54,161 Added 279.32%	73,551 $1.36 Million
Q2 2017 Nov 09, 2017	BUY	N/A	19,390	19,390 $340,000

Others Institutions Holding MGNX

# of Institutions

131

Shares Held

56M

Call Options Held

28.3K

Put Options Held

197K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $128M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Macrogenics Inc Transaction History